Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Evelyn Douglas is active.

Publication


Featured researches published by Evelyn Douglas.


BMC Molecular Biology | 2001

Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer

Sally-Anne Stephenson; Stefan Slomka; Evelyn Douglas; Peter Hewett; Jennifer E. Hardingham

BackgroundWe have used commercially available cDNA arrays to identify EphB4 as a gene that is up-regulated in colon cancer tissue when compared with matched normal tissue from the same patient.ResultsQuantitative RT-PCR analysis of the expression of the EphB4 gene has shown that its expression is increased in 82% of tumour samples when compared with the matched normal tissue from the same patient. Using immunohistochemistry and Western analysis techniques with an EphB4-specific antibody, we also show that this receptor is expressed in the epithelial cells of the tumour tissue and either not at all, or in only low levels, in the normal tissue.ConclusionThe results presented here supports the emerging idea that Eph receptors play a role in tumour formation and suggests that further elucidation of this signalling pathway may identify useful targets for cancer treatment therapies.


American Journal of Human Genetics | 2012

A noncoding, regulatory mutation implicates HCFC1 in nonsyndromic intellectual disability

Lingli Huang; Lachlan A. Jolly; Saffron A. G. Willis-Owen; Alison Gardner; Raman Kumar; Evelyn Douglas; Cheryl Shoubridge; Dagmar Wieczorek; Andreas Tzschach; Monika Cohen; Anna Hackett; Michael Field; Guy Froyen; Hao Hu; Stefan A. Haas; Hans-Hilger Ropers; Vera M. Kalscheuer; Mark Corbett; Jozef Gecz

The discovery of mutations causing human disease has so far been biased toward protein-coding regions. Having excluded all annotated coding regions, we performed targeted massively parallel resequencing of the nonrepetitive genomic linkage interval at Xq28 of family MRX3. We identified in the binding site of transcription factor YY1 a regulatory mutation that leads to overexpression of the chromatin-associated transcriptional regulator HCFC1. When tested on embryonic murine neural stem cells and embryonic hippocampal neurons, HCFC1 overexpression led to a significant increase of the production of astrocytes and a considerable reduction in neurite growth. Two other nonsynonymous, potentially deleterious changes have been identified by X-exome sequencing in individuals with intellectual disability, implicating HCFC1 in normal brain function.


Human Molecular Genetics | 2015

Mutations of protocadherin 19 in female epilepsy (PCDH19-FE) lead to allopregnanolone deficiency

Chuan Tan; Chloe Shard; Enzo Ranieri; Kim Hynes; Duyen H. Pham; Damian Leach; Grant Buchanan; Mark Corbett; Cheryl Shoubridge; Raman Kumar; Evelyn Douglas; Lam Son Nguyen; Jacinta M. McMahon; Lynette G. Sadleir; Nicola Specchio; Carla Marini; Renzo Guerrini; Rikke S. Møller; Christel Depienne; Eric Haan; Paul Q. Thomas; Samuel F. Berkovic; Ingrid E. Scheffer; Jozef Gecz

Protocadherin 19 (PCDH19) female limited epilepsy (PCDH19-FE; also known as epilepsy and mental retardation limited to females, EFMR; MIM300088) is an infantile onset epilepsy syndrome with or without intellectual disability (ID) and autism. We investigated transcriptomes of PCDH19-FE female and control primary skin fibroblasts, which are endowed to metabolize neurosteroid hormones. We identified a set of 94 significantly dysregulated genes in PCDH19-FE females. Intriguingly, 43 of the 94 genes (45.7%) showed gender-biased expression; enrichment of such genes was highly significant (P = 2.51E-47, two-tailed Fisher exact test). We further investigated the AKR1C1-3 genes, which encode crucial steroid hormone-metabolizing enzymes whose key products include allopregnanolone and estradiol. Both mRNA and protein levels of AKR1C3 were significantly decreased in PCDH19-FE patients. In agreement with this, the blood levels of allopregnanolone were also (P < 0.01) reduced. In conclusion, we show that the deficiency of neurosteroid allopregnanolone, one of the most potent GABA receptor modulators, may contribute to PCDH19-FE. Overall our findings provide evidence for a role of neurosteroids in epilepsy, ID and autism and create realistic opportunities for targeted therapeutic interventions.


American Journal of Human Genetics | 2015

THOC2 Mutations Implicate mRNA-Export Pathway in X-Linked Intellectual Disability

Raman Kumar; Mark Corbett; Bregje W.M. van Bon; Joshua A. Woenig; Lloyd Weir; Evelyn Douglas; Kathryn Friend; Alison Gardner; Marie Shaw; Lachlan A. Jolly; Chuan Tan; Matthew Hunter; Anna Hackett; Michael Field; Elizabeth E. Palmer; Melanie Leffler; Carolyn Rogers; Jackie Boyle; Melanie Bienek; Corinna Jensen; Griet Van Buggenhout; Hilde Van Esch; Katrin Hoffmann; Martine Raynaud; Huiying Zhao; Robin Reed; Hao Hu; Stefan A. Haas; Eric Haan; Vera M. Kalscheuer

Export of mRNA from the cell nucleus to the cytoplasm is essential for protein synthesis, a process vital to all living eukaryotic cells. mRNA export is highly conserved and ubiquitous. Mutations affecting mRNA and mRNA processing or export factors, which cause aberrant retention of mRNAs in the nucleus, are thus emerging as contributors to an important class of human genetic disorders. Here, we report that variants in THOC2, which encodes a subunit of the highly conserved TREX mRNA-export complex, cause syndromic intellectual disability (ID). Affected individuals presented with variable degrees of ID and commonly observed features included speech delay, elevated BMI, short stature, seizure disorders, gait disturbance, and tremors. X chromosome exome sequencing revealed four missense variants in THOC2 in four families, including family MRX12, first ascertained in 1971. We show that two variants lead to decreased stability of THOC2 and its TREX-complex partners in cells derived from the affected individuals. Protein structural modeling showed that the altered amino acids are located in the RNA-binding domains of two complex THOC2 structures, potentially representing two different intermediate RNA-binding states of THOC2 during RNA transport. Our results show that disturbance of the canonical molecular pathway of mRNA export is compatible with life but results in altered neuronal development with other comorbidities.


American Journal of Human Genetics | 2017

YY1 Haploinsufficiency Causes an Intellectual Disability Syndrome Featuring Transcriptional and Chromatin Dysfunction

Michele Gabriele; Anneke T. Vulto-van Silfhout; Pierre Luc Germain; Alessandro Vitriolo; Raman Kumar; Evelyn Douglas; Eric Haan; Kenjiro Kosaki; Toshiki Takenouchi; Anita Rauch; Katharina Steindl; Eirik Frengen; Doriana Misceo; Christeen Ramane J. Pedurupillay; Petter Strømme; Jill A. Rosenfeld; Yunru Shao; William J. Craigen; Christian P. Schaaf; David Rodriguez-Buritica; Laura S. Farach; Jennifer Friedman; Perla Thulin; Scott D. McLean; Kimberly M. Nugent; Jenny Morton; Jillian Nicholl; Joris Andrieux; Asbjørg Stray-Pedersen; Pascal Chambon

Yin and yang 1 (YY1) is a well-known zinc-finger transcription factor with crucial roles in normal development and malignancy. YY1 acts both as a repressor and as an activator of gene expression. We have identified 23 individuals with de novo mutations or deletions of YY1 and phenotypic features that define a syndrome of cognitive impairment, behavioral alterations, intrauterine growth restriction, feeding problems, and various congenital malformations. Our combined clinical and molecular data define “YY1 syndrome” as a haploinsufficiency syndrome. Through immunoprecipitation of YY1-bound chromatin from affected individuals’ cells with antibodies recognizing both ends of the protein, we show that YY1 deletions and missense mutations lead to a global loss of YY1 binding with a preferential retention at high-occupancy sites. Finally, we uncover a widespread loss of H3K27 acetylation in particular on the YY1-bound enhancers, underscoring a crucial role for YY1 in enhancer regulation. Collectively, these results define a clinical syndrome caused by haploinsufficiency of YY1 through dysregulation of key transcriptional regulators.


Human Molecular Genetics | 2015

Increased STAG2 dosage defines a novel cohesinopathy with intellectual disability and behavioral problems

Raman Kumar; Mark Corbett; Bregje W.M. van Bon; Alison Gardner; Joshua A. Woenig; Lachlan A. Jolly; Evelyn Douglas; Kathryn Friend; Chuan Tan; Hilde Van Esch; Maureen Holvoet; Martine Raynaud; Michael Field; Melanie Leffler; B Budny; Marzena Wisniewska; Magdalena Badura-Stronka; Anna Latos-Bielenska; Jacqueline R. Batanian; Jill A. Rosenfeld; Lina Basel-Vanagaite; Corinna Jensen; Melanie Bienek; Guy Froyen; Reinhard Ullmann; Hao Hu; Michael I. Love; Stefan A. Haas; Pawel Stankiewicz; Sau Wai Cheung

Next generation genomic technologies have made a significant contribution to the understanding of the genetic architecture of human neurodevelopmental disorders. Copy number variants (CNVs) play an important role in the genetics of intellectual disability (ID). For many CNVs, and copy number gains in particular, the responsible dosage-sensitive gene(s) have been hard to identify. We have collected 18 different interstitial microduplications and 1 microtriplication of Xq25. There were 15 affected individuals from 6 different families and 13 singleton cases, 28 affected males in total. The critical overlapping region involved the STAG2 gene, which codes for a subunit of the cohesin complex that regulates cohesion of sister chromatids and gene transcription. We demonstrate that STAG2 is the dosage-sensitive gene within these CNVs, as gains of STAG2 mRNA and protein dysregulate disease-relevant neuronal gene networks in cells derived from affected individuals. We also show that STAG2 gains result in increased expression of OPHN1, a known X-chromosome ID gene. Overall, we define a novel cohesinopathy due to copy number gain of Xq25 and STAG2 in particular.


PLOS Genetics | 2014

FRA2A is a CGG repeat expansion associated with silencing of AFF3.

Sofie Metsu; Liesbeth Rooms; Jacqueline K. Rainger; Martin S. Taylor; Hemant Bengani; David I. Wilson; Chandra Sekhar Reddy Chilamakuri; Harris Morrison; Geert Vandeweyer; Edwin Reyniers; Evelyn Douglas; Geoffrey Thompson; Eric Haan; Jozef Gecz; David Fitzpatrick; R. Frank Kooy

Folate-sensitive fragile sites (FSFS) are a rare cytogenetically visible subset of dynamic mutations. Of the eight molecularly characterized FSFS, four are associated with intellectual disability (ID). Cytogenetic expression results from CGG tri-nucleotide-repeat expansion mutation associated with local CpG hypermethylation and transcriptional silencing. The best studied is the FRAXA site in the FMR1 gene, where large expansions cause fragile X syndrome, the most common inherited ID syndrome. Here we studied three families with FRA2A expression at 2q11 associated with a wide spectrum of neurodevelopmental phenotypes. We identified a polymorphic CGG repeat in a conserved, brain-active alternative promoter of the AFF3 gene, an autosomal homolog of the X-linked AFF2/FMR2 gene: Expansion of the AFF2 CGG repeat causes FRAXE ID. We found that FRA2A-expressing individuals have mosaic expansions of the AFF3 CGG repeat in the range of several hundred repeat units. Moreover, bisulfite sequencing and pyrosequencing both suggest AFF3 promoter hypermethylation. cSNP-analysis demonstrates monoallelic expression of the AFF3 gene in FRA2A carriers thus predicting that FRA2A expression results in functional haploinsufficiency for AFF3 at least in a subset of tissues. By whole-mount in situ hybridization the mouse AFF3 ortholog shows strong regional expression in the developing brain, somites and limb buds in 9.5–12.5dpc mouse embryos. Our data suggest that there may be an association between FRA2A and a delay in the acquisition of motor and language skills in the families studied here. However, additional cases are required to firmly establish a causal relationship.


Human Mutation | 2018

Severe neurocognitive and growth disorders due to variation in THOC2, an essential component of nuclear mRNA export machinery

Raman Kumar; Alison Gardner; Claire C. Homan; Evelyn Douglas; Mefford Hc; Dagmar Wieczorek; Hermann-Josef Lüdecke; Zornitza Stark; Simon Sadedin; Catherine Nowak; Jessica Douglas; Gretchen Parsons; Paul R. Mark; Lourdes Loidi; Gail E. Herman; Theresa Mihalic Mosher; Meredith K. Gillespie; Lauren Brady; Mark A. Tarnopolsky; Irene Madrigal; Jesús Eiris; Laura Domènech Salgado; Raquel Rabionet; Tim M. Strom; Naoko Ishihara; Hidehito Inagaki; Hiroki Kurahashi; Tracy Dudding-Byth; Elizabeth E. Palmer; Michael Field

Highly conserved TREX‐mediated mRNA export is emerging as a key pathway in neuronal development and differentiation. TREX subunit variants cause neurodevelopmental disorders (NDDs) by interfering with mRNA export from the cell nucleus to the cytoplasm. Previously we implicated four missense variants in the X‐linked THOC2 gene in intellectual disability (ID). We now report an additional six affected individuals from five unrelated families with two de novo and three maternally inherited pathogenic or likely pathogenic variants in THOC2 extending the genotypic and phenotypic spectrum. These comprise three rare missense THOC2 variants that affect evolutionarily conserved amino acid residues and reduce protein stability and two with canonical splice‐site THOC2 variants that result in C‐terminally truncated THOC2 proteins. We present detailed clinical assessment and functional studies on a de novo variant in a female with an epileptic encephalopathy and discuss an additional four families with rare variants in THOC2 with supportive evidence for pathogenicity. Severe neurocognitive features, including movement and seizure disorders, were observed in this cohort. Taken together our data show that even subtle alterations to the canonical molecular pathways such as mRNA export, otherwise essential for cellular life, can be compatible with life, but lead to NDDs in humans.


Faculty of Health; Institute of Health and Biomedical Innovation | 2015

Anti-tumour effects of antibodies targeting the extracellular cysteine-rich region of the receptor tyrosine kinase EphB4

Sally-Anne Stephenson; Evelyn Douglas; Inga Mertens-Walker; Jessica E. Lisle; Mohanan S.N. Maharaj; Adrian C. Herington


Abstract book | 2015

Increased STAG2 dosage defines a novel cohesinopathy with intellectual disability and behavioural problems

Raman Kumar; Mark Corbett; Bwm Van den Bon; Alison Gardner; Joshua A. Woenig; Lachlan A. Jolly; Evelyn Douglas; Kathryn Friend; Chuan Tan; Hilde Van Esch; Maureen Holvoet; Martine Raynaud; Michael Field; Melanie Leffler; B Budny; Marzena Wisniewska; Magdalena Badura-Stronka; Anna Latos-Bielenska; Jacqueline R. Batanian; Ja Rosenveld; Lina Basel-Vanagaite; C Jenssen; Melanie Bienek; R Ullman; Hao Hu; Mi Lovel; Stefan A. Haas; P Stankiewics; Sau Wai Cheung; Anne Baxendale

Collaboration


Dive into the Evelyn Douglas's collaboration.

Top Co-Authors

Avatar

Raman Kumar

University of Adelaide

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Chuan Tan

University of Adelaide

View shared research outputs
Top Co-Authors

Avatar

Eric Haan

University of Adelaide

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jozef Gecz

University of Adelaide

View shared research outputs
Researchain Logo
Decentralizing Knowledge